Detalhe da pesquisa
1.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
N Engl J Med
; 388(23): 2145-2158, 2023 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36972026
2.
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Int J Gynecol Cancer
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627035
3.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965291
4.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355448
5.
Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features.
Int J Gynecol Cancer
; 2023 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38054268
6.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Br J Cancer
; 127(8): 1479-1486, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869143
7.
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
Ann Surg Oncol
; 29(13): 8302-8314, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35976464
8.
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Int J Mol Sci
; 23(7)2022 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35408919
9.
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells.
Int J Mol Sci
; 23(2)2022 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35055018
10.
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition.
Int J Mol Sci
; 23(10)2022 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35628590
11.
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Gynecol Oncol
; 161(3): 755-761, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33888336
12.
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey.
Int J Gynecol Cancer
; 31(10): 1363-1368, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34426526
13.
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Int J Gynecol Cancer
; 31(7): 1031-1036, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33990353
14.
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
Int J Mol Sci
; 22(8)2021 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33921561
15.
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Gynecol Oncol
; 156(1): 38-44, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31699415
16.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Int J Mol Sci
; 21(12)2020 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575899
17.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Gynecol Oncol
; 153(3): 535-540, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30979589
18.
Veliparib: a new therapeutic option in ovarian cancer?
Future Oncol
; 15(17): 1975-1987, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31074636
19.
Ovarian Cancer Immunotherapy: Turning up the Heat.
Int J Mol Sci
; 20(12)2019 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31208030
20.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Int J Mol Sci
; 20(9)2019 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31083638